The Treaty of Lisbon has enhanced the importance of health policy, stipulating that ‘a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities’. Primary responsibility for health protection and, in particular, healthcare systems continues to lie with the Member States. However, the EU has an important role to play in improving public health, preventing and managing diseases, mitigating sources of danger to human health, and harmonising health strategies between Member States. The EU has successfully implemented a comprehensive policy, through the ‘Health for Growth’ health strategy and its action programme (2014-2020) and a body of secondary legislation. The European Social Fund Plus (ESF+) will continue to provide funding during the 2021-2027 programming period.
Medicines and medical devices are subject to the rules of the single market and have a direct impact on people’s health. A robust legal framework is in place to protect public health and guarantee the safety of these products. It covers the full cycle, from trials and testing, to authorisation for placement on the market, to surveillance and recall. Access to affordable medicines, the fight against antimicrobial resistance, the ethical conduct of clinical trials, and incentives to research and development are just some of the key issues the EU deals with in this field. In order to keep up with scientific and technological advancement and respond to emerging health threats, legislative and policy measures are subject to regular evaluation and follow-up.